RxDoctor Payments Data

Frank Melidona, DO

Family Medicine · The Villages, FLNPI 1497756878

Payments from drug & device makers

$2,341in general payments, 2019–2025

Across 22 payments — averaging $106.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$548
  • Averitas Pharma Inc.$256
  • Novo Nordisk$226
  • Sanofi-aventis U.S. LLC$199
  • Abbott$189
  • GSK$125
  • plus $798 from 7 others

What the payments were for

  • Food & beverage$2,341100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,341 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$10,729
Medicare patients
50
Services billed
1,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$189,011
XareltoRivaroxaban25$33,407
OzempicSemaglutide27$31,758
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$30,137
JanuviaSitagliptin Phosphate13$25,399
TrulicityDulaglutide11$23,121
JardianceEmpagliflozin13$23,076
Omeprazole379$11,852
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$10,966
ShingrixVaricella-Zoster Ge/As01b/Pf34$7,415
Gabapentin266$7,341
Atorvastatin Calcium573$5,124
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen115$4,988
Levothyroxine Sodium519$4,843
Metoprolol Succinate413$4,284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Shingrix$125$37,55267 claims
Boehringer IngelheimJardiance, Stiolto Respimat$125$34,04127 claims
Novo NordiskOzempic$226$31,75827 claims
Lilly USA, LLCTrulicity$548$23,12111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →